 |
|
|
| |
CLINICAL IMPACT OF ANTIRETROVIRAL AGENTS USED IN OPTIMIZED
BACKGROUND THERAPY WITH FOSTEMSAVIR IN HEAVILY
TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY
ANALYSES OF THE PHASE 3 BRIGHTE STUDY
|
| |
| |
IAS 2021 July 18-22
Peter Ackerman,1 Timothy Wilkin,2 Amy Pierce,3 Shiven Chabria,1 Marcia Wang,4 Andrew Clark,5 Max Lataillade1
1ViiV Healthcare, Branford, CT, USA; 2Weill Cornell Medicine, New York, NY, USA; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4GlaxoSmithKline, Upper Providence Township, PA, USA; 5ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
